US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunovant, Inc.

6.86

+0.0000

Volume:- -

Turnover:- -

Market Cap:432.28M

PE:-7.79

High:6.86

Open:6.86

Low:6.86

Close:6.86

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Immunovant, Inc.

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

- -

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMVTW/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMVTW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMVTW\",,,,,undefined,":{"symbol":"IMVTW","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":6.86,"timestamp":1592251200000,"preClose":6.86,"halted":3,"volume":0,"delay":0,"floatShares":11447972,"shares":63014824,"eps":-0.881038,"marketStatus":"Halted","change":0,"latestTime":"03-31 10:25:03 EDT","open":6.86,"high":6.86,"low":6.86,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.881038,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743451200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":6.86,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMVTW\",,,,,undefined,":{"symbol":"IMVTW","floatShares":11447972,"roa":"--","roe":"--","lyrEps":-0.630873,"shares":63014824,"dividePrice":0,"high":6.86,"amplitude":0,"preClose":6.86,"low":6.86,"week52Low":0.21,"pbRate":"3.86","week52High":8.01,"institutionHeld":0,"latestPrice":6.86,"eps":-0.881038,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.881038,"open":6.86,"prevYearClose":2},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0277},{"period":"1year","weight":0.0623},{"period":"ytd","weight":-0.0519}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"IMVTW\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMVTW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-02-14","symbol":"IMVTW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1581656400000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMVTW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMVTW\",market:\"US\",delay:false,,,undefined,":{}}}